会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • Endothelial cell growth factor methods of isolation and expression
    • 内皮细胞生长因子分离和表达方法
    • US20060025577A1
    • 2006-02-02
    • US11210001
    • 2005-08-22
    • Napoleone FerraraDenis GospodarowiczJean Plouet
    • Napoleone FerraraDenis GospodarowiczJean Plouet
    • A61K38/18C07K14/59
    • C07K14/52A61K38/1866
    • A novel growth factor specific for vascular endothelial cells has been identified in conditioned medium of bovine pituitary derived folliculo stellate cells. This factor, named folliculo stellate derived growth facto (FSdGF) or vascular endothelial growth factor (VEGF), was purified to homogeneity by a combination of heparin sepharose affinity chromatography, Bio Gel P-60 exclusion chromatography, Mono S ion exchange chromatography and hydrophobic chromatography on a C4 reverse phase HPLC column. The factor is also found in the murine AtT-20 cell line. Alternatively, the growth factor is purified by a first reverse phase HPLC using acetonitrile gradient followed by a second reverse phase HPLC using an isopropanol gradient. FSdGF, having a molecular weight of about 43,000 da, was characterized as a glycoprotein composed of two homologous sub units with MW of about 23 kDa. FSdGF was a potent mitogen for vascular endothelial cells with activity detectable at 10 pg/ml and saturation at 500 pg/ml. It did not stimulate the proliferation of other cell types such as bovine corneal endothelial cells, adrenal cortex cells, granulosa cells, BALB/MK cells or BHK-21 cells. Microsequencing revealed an amino terminal sequence containing no significant homology to any known protein. The release of FSdGF by pituitary cells and its unique target cell specificity indicate that FSdGF is useful in angiogenesis.
    • 已经在牛垂体衍生的卵泡星状细胞的条件培养基中鉴定了对血管内皮细胞特异性的新型生长因子。 通过肝素琼脂糖亲和层析,Bio Gel P-60排除色谱法,Mono S离子交换色谱法和疏水色谱法的组合,将这一命名为卵泡星状衍生生长因子(FSdGF)或血管内皮生长因子(VEGF)的因子纯化至均质 在C4反相HPLC柱上。 该因子也在鼠AtT-20细胞系中发现。 或者,通过使用乙腈梯度的第一反相HPLC纯化生长因子,然后使用异丙醇梯度进行第二反相HPLC纯化生长因子。 具有约43,000Da分子量的FSdGF被表征为由具有约23kDa的MW的两个同源亚单位组成的糖蛋白。 FSdGF是血管内皮细胞的有效促分裂原,其活性可检测为10 pg / ml,饱和度为500 pg / ml。 它不刺激其他细胞类型的增殖,如牛角膜内皮细胞,肾上腺皮质细胞,颗粒细胞,BALB / MK细胞或BHK-21细胞。 微测序显示与任何已知蛋白质没有显着同源性的氨基末端序列。 垂体细胞释放FSdGF及其独特的靶细胞特异性表明FSdGF可用于血管发生。
    • 7. 发明申请
    • Truncated keratinocyte growth factor (KGF) having increased biological activity
    • 截短的角质形成细胞生长因子(KGF)具有增加的生物活性
    • US20050090445A1
    • 2005-04-28
    • US10998425
    • 2004-11-29
    • Denis GospodarowiczFrank Masiarz
    • Denis GospodarowiczFrank Masiarz
    • A61K38/00A61K47/48C07K14/50A61K38/18A61K39/02C07K14/415C07K14/475
    • C07K14/50A61K38/00A61K47/6415A61K47/642
    • The present invention relates to a keratinocyte growth factor fragment, KGFdes1-23, or an analog thereof that is composed of a portion of an amino acid sequence of mature, full length keratinocyte growth factor, KGF163. The fragment exhibits at least a 2-fold increase in mitogenic activity as compared to a mature, recombinant keratinocyte growth factor, rKGF, but lacks a sequence comprising the first 23 amino acid residues, C-N-D-M-T-P-E-Q-M-A-T-N-V-N-C-S-S-P-E-R-H-T-R- (SEQ ID NO: 2) of the KGF163 N-terminus. The present invention also relates to a DNA molecule encoding KGFdes1-23, an expression vector and a transformed host containing the DNA molecule, and a method of producing KGFdes1-23 by culturing the transformed host. The present invention further relates to a conjugate of KGFdes1-23 and a toxin molecule, and the use thereof for treatment of hyperproliferative disease of the epidernis. Moreover, the present invention relates to a therapeutic composition containing KGFdes1-23 and a pharmaceutically acceptable carrier and the use thereof for wound healing purposes.
    • 本发明涉及由成熟的全长角质形成细胞生长因子的一部分氨基酸序列组成的角质形成细胞生长因子片段,KGF 或其类似物,KGF 163 。 与成熟的重组角质形成细胞生长因子rKGF相比,该片段显示出促有丝分裂活性的至少2倍的增加,但是缺少包含前23个氨基酸残基的序列CNDMTPEQMATNVNCSSPERH-TR-(SEQ ID NO:2) KGF 163 N末端。 本发明还涉及编码KGF Sub1-23的DNA分子,表达载体和含有该DNA分子的转化宿主,以及生产KGF 通过培养转化的宿主。 本发明进一步涉及一种KGF des 1>>>>>>。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。 此外,本发明涉及含有KGF和其药学上可接受的载体的治疗组合物及其用于伤口愈合目的的用途。